IMVT · Immunovant, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $456.66M | $360.92M | $212.93M | $101.81M | $101.81M | $68.60M |
| SG&A | $76.24M | $77.23M | $57.28M | $48.02M | $54.23M | $39.51M |
| Total Operating Expenses | $532.90M | $438.15M | $282.71M | $218.28M | $156.03M | $108.12M |
| D&A | $409.0K | $377.0K | $231.0K | $193.0K | $126.0K | $65.0K |
| Operating Income | ($505.39M) | ($412.95M) | ($258.77M) | ($210.95M) | ($107.79M) | ($107.79M) |
| Interest Expense | - | - | - | - | - | $0 |
| Income Tax | $215.0K | $891.0K | $567.0K | $9.0K | ($84.0K) | ($358.0K) |
| Net Income | ($505.61M) | ($413.84M) | ($259.34M) | ($210.96M) | ($156.73M) | ($107.43M) |
| EPS - Basic | ($2.77) | ($2.73) | ($1.88) | ($1.71) | ($1.43) | - |
| EPS - Diluted | ($2.77) | ($2.73) | ($1.88) | ($1.71) | ($1.43) | - |
Balance Sheet
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $902.11M | $713.97M | $635.37M | $376.53M | $493.82M | $400.15M |
| Accounts Receivable | $1.13M | $2.08M | $5.34M | $700.0K | $596.0K | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $7.54M | $17.66M | $7.16M | $1.35M | $18.63M | $2.43M |
| Current Assets | $948.82M | $767.66M | $665.77M | $404.33M | $512.93M | $409.01M |
| Total Assets | $957.01M | $776.22M | $666.37M | $405.84M | $515.56M | $412.49M |
| Current Liabilities | $104.42M | $68.78M | $48.61M | $43.30M | $44.52M | $18.77M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $104.42M | $68.78M | $48.61M | $43.34M | $45.74M | $21.01M |
| Stockholders' Equity | $852.59M | $707.45M | $617.76M | $362.49M | $469.82M | $391.48M |
| Retained Earnings | ($1.75B) | ($1.24B) | ($825.68M) | ($566.35M) | ($355.39M) | ($198.66M) |
Cash Flow
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($407.31M) | ($375.87M) | ($214.23M) | ($188.19M) | ($106.11M) | ($83.33M) |
| Investing Cash Flow | ($8.0K) | ($759.0K) | ($360.0K) | ($197.0K) | ($254.0K) | ($210.0K) |
| Financing Cash Flow | $595.76M | $454.49M | $472.43M | $70.89M | $200.13M | $383.11M |
| CapEx | $8.0K | $759.0K | $360.0K | $197.0K | $254.0K | $210.0K |
| Free Cash Flow | ($407.32M) | ($376.63M) | ($214.59M) | ($188.39M) | ($106.37M) | ($83.54M) |
Ratios
| Metric | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | 0.81 | 0.91 | 0.83 | 0.89 | 0.68 | 0.78 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -52.8% | -53.3% | -38.9% | -52.0% | -30.4% | -26.0% |
| Return on equity | -59.3% | -58.5% | -42.0% | -58.2% | -33.4% | -27.4% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 9.09 | 11.16 | 13.70 | 9.34 | 11.52 | 21.79 |
| Quick ratio | 9.09 | 11.16 | 13.70 | 9.34 | 11.52 | 21.79 |
| Cash ratio | 8.64 | 10.38 | 13.07 | 8.70 | 11.09 | 21.32 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 1.12 | 1.10 | 1.08 | 1.12 | 1.10 | 1.05 |
| Liabilities / Assets | 0.11 | 0.09 | 0.07 | 0.11 | 0.09 | 0.05 |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 5.3x | 3.7x | 7.2x | 5.3x | 1.0x | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | -22.4% | -59.6% | -22.7% | -95.7% | - | -62.6% |
| Net income growth (YoY) | -22.2% | -59.6% | -22.9% | -34.6% | - | -61.8% |
| EPS growth (YoY) | -1.5% | -45.2% | -9.9% | -19.6% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | -8.1% | -75.5% | -13.9% | -77.1% | - | -56.5% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 20.5% | 14.5% | 70.4% | -22.8% | - | 316.2% |
Stability scores
Piotroski F-score
FY 2026 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Immunovant against the 5 most active filers in the same SIC group.